Riekje Winzer

6PUBLICATIONS
31CO-AUTHORS
Biologically active moleculesMedical biochemistry - proteins and peptides (incl. medical proteomics)Proteomics and intermolecular interactions (excl. medical proteomics)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 01, 2026
Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of Cancer.

|Dec 18, 2025
Reliable Determination of ATP and Its Metabolites by LC-MS Using Blood Collection Tubes with and without Ectonucleotidase Inhibitors.

Riekje Winzer, Johanna Hiefner, Romy Hackbusch

|Dec 18, 2024
ENPP1/CD203a-targeting heavy-chain antibody reveals cell-specific expression on human immune cells.

Hannah Lorenz, Stephan Menzel, Nataliia Roshchyna

|Sep 30, 2022
P2X7 is expressed on human innate-like T lymphocytes and mediates susceptibility to ATP-induced cell death.

Riekje Winzer, Arnau Serracant-Prat, Valerie J Brock

|Aug 18, 2022
Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.

Laura Schäkel, Salahuddin Mirza, Riekje Winzer

|Oct 09, 2021
CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression.

Enja Schneider, Riekje Winzer, Anne Rissiek

Pageof 1

Frequent Collaborators

3 joint publications

Enja Schneider

3 joint publications

Björn Rissiek

3 joint publications

Eva Tolosa

3 joint publications

Christa E Müller